BRAMITOB

This brand name is authorized in Austria, Brazil, Croatia, Estonia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Spain, UK.

Active ingredients

The drug BRAMITOB contains one active pharmaceutical ingredient (API):

1	Tobramycin UNII VZ8RRZ51VK - TOBRAMYCIN
	Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts primarily by disrupting protein synthesis leading to altered cell membrane permeability, progressive disruption of the cell envelope and eventual cell death. It is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.
	Read more about Tobramycin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01GB01	Tobramycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01G Aminoglycoside antibacterials → J01GB Other aminoglycosides
Discover more medicines within J01GB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	508503903131313
EE	Ravimiamet	1438499
ES	Centro de información online de medicamentos de la AEMPS	68621
GB	Medicines & Healthcare Products Regulatory Agency	147912
HR	Agencija za lijekove i medicinske proizvode	HR-H-873495110
IE	Health Products Regulatory Authority	88749
IL	מִשְׂרַד הַבְּרִיאוּת	6881
IT	Agenzia del Farmaco	036646038
LT	Valstybinė vaistų kontrolės tarnyba	1037888, 1063116, 1063117, 1071192
NL	Z-Index G-Standaard, PRK	830801
PL	Rejestru Produktów Leczniczych	100175593